Georgina Galicia

Dr. Georgina Galicia

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Cell
Verified
Journal Article
Closed access
OROlga L. Rojas
Olga L. Rojas
APAnne-Katrin Pröbstel
Anne-Katrin Pröbstel
EPElisa A. Porfilio
Elisa A. Porfilio
AWAngela A. Wang
Angela A. Wang
MCMarc Charabati
Marc Charabati
JGJennifer L. Gommerman
Jennifer L. Gommerman

1 December 2015 in Immunity
Verified
Journal Article
Closed access
NPNatalia B. Pikor
Natalia B. Pikor
JAJillian L. Astarita
Jillian L. Astarita
LSLeslie Summers-Deluca
Leslie Summers-Deluca
GGGeorgina Galicia
Georgina Galicia
JQJoy Qu
Joy Qu
JGJennifer L. Gommerman
Jennifer L. Gommerman

1 October 2009 in Neuro-Oncology
Verified
Journal Article
Open access
WMWim Maes
Wim Maes
GGGeorgina Galicia
Georgina Galicia
BVBert Verbinnen
Bert Verbinnen
LBLouis Boon
Louis Boon
SVSteven De Vleeschouwer
Steven De Vleeschouwer
SGStefaan W Van Gool
Stefaan W Van Gool
We studied the feasibility, efficacy, and mechanisms of dendritic cell (DC) immunotherapy against murine malignant glioma in the experimental GL261 i

1 May 2003 in International Immunopharmacology
Verified
Journal Article
Closed access
GGGeorgina Galicia
Georgina Galicia
RLRosario Leyva
Rosario Leyva
ETEda Tenorio
Eda Tenorio
POPatricia Ostrosky-Wegman
Patricia Ostrosky-Wegman
RSRafael Saavedra
Rafael Saavedra

15 July 2008 in The Journal of Immunology
Verified
Journal Article
Closed access
BVBert Verbinnen
Bert Verbinnen
ABAn D Billiau
An D Billiau
JVJan Vermeiren
Jan Vermeiren
GGGeorgina Galicia
Georgina Galicia
DBDominique M A Bullens
Dominique M A Bullens
JCJan L Ceuppens
Jan L Ceuppens
Blocking of costimulatory signals for T cell activation leads to tolerance in several transplantation models, but the underlying mechanisms are incompletely understood. We analyzed the involvement of regulatory T cells (Treg) and deletion of alloreactive cells in the induction and maintenance of tolerance after costimulation blockade in a mouse model of graft-vs-host reaction. Injection of splenocytes from the C57BL/6 parent strain into a sublethally irradiated F1 offspring (C57BL/6 × C3H) induced a GVHR characterized by severe pancytopenia. Treatment with anti-CD40L mAb and CTLA4-Ig every 3 days during 3 wk after splenocyte injection prevented disease development and induced a long-lasting state of stable mixed chimerism (>120 days). In parallel, host-specific tolerance was achieved as demonstrated by lack of host-directed alloreactivity of donor-type T cells in vitro and in vivo. Chimerism and tolerance were also obtained after CD25+ cell-depleted splenocyte transfer, showing that CD25+ natural Treg are not essential for tolerance induction. We further show that costimulation blockade results in enhanced Treg cell activity at early time points (days 6–30) after splenocyte transfer. This was demonstrated by the presence of a high percentage of Foxp3+ cells among donor CD4+ cells in the spleen of treated animals, and our finding that isolated donor-type T cells at an early time point (day 30) after splenocyte transfer displayed suppressive capacity in vitro. At later time points (>30 days after splenocyte transfer), clonal deletion of host-reactive T cells was found to be a major mechanism responsible for tolerance.

15 March 2010 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
LDLeslie E. Summers Deluca
Leslie E. Summers Deluca
NPNatalia B. Pikor
Natalia B. Pikor
JOJennifer O’lEary
Jennifer O’lEary
GGGeorgina Galicia
Georgina Galicia
LWLesley A Ward
Lesley A Ward
JGJennifer L. Gommerman
Jennifer L. Gommerman
Experimental autoimmune encephalomyelitis (EAE) is a rodent model of multiple sclerosis that is executed in animals by immunization with myelin Ag in adjuvant. The SJL/J autoimmune-prone strain of mouse has been used to model relapsing–remitting multiple sclerosis. However, significant variations in peak scores, timing of onset, and incidence are observed among laboratories, with the postacute (relapse) phase of the disease exhibiting significant inconsistency. We characterized two substrains of SJL/J mice that exhibit profoundly different EAE disease parameters. Induction of EAE in the first SJL/J substrain resulted in many cases of chronic EAE that was dominated by an aggressive B cell response to the immunizing Ag and to endogenous CNS Ags. In contrast, the other SJL/J substrain exhibited a relapsing–remitting form of EAE concomitant with an elevated number of cytokine-producing CD4+ T cells in the CNS. Exploiting these interstrain differences, we performed a genome-wide copy number analysis on the two disparate SJL/J substrains and discovered numerous gene-dosage differences. In particular, one inflammation-associated gene, Naip1, was present at a higher copy number in the SJL/J substrain that exhibited relapsing–remitting EAE. These results demonstrate that substrain differences, perhaps at the level of genomic copy number, can account for variability in the postacute phase of EAE and may drive chronic versus relapsing disease.